Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab, Fruquintinib, and FOLFOX in pMMR/MSS Colorectal Cancer
NCT07446465Phase 4Not yet recruiting
- Start
- Mar 2026
- Primary completion
- Jan 2027
- Modality
- Immune Checkpoint Inhibitors, Fragment-Derived Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of serplulimab, fruquintinib in colorectal cancer (CRC). Planned start Mar 2026; status: not yet recruiting.
02
Drugs
serplulimabfruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07446465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07446465.